population health

Research in Review

Immunotherapies May Pose Severe Heart Risk

11/04/2016

JCP Editors

Researchers have identified a serious and potentially fatal adverse event associated with immunology drugs, according to a study published in the New England Journal of Medicine. Immune checkpoint inhibitors have...

...

11/04/2016

Journal of Clinical Pathways

Research in Review

Standard of Care Underutilized for Cervical Cancer

11/04/2016

JCP Editors

Though proven to offer superior outcomes versus other treatment regimens, less than half of patients receive standard of care for locally advanced cervical cancer, according to a study published in Gynecologic...

Though...

11/04/2016

Journal of Clinical Pathways

Research in Review

High Potential for Drug-Drug Interactions With New Antineoplastic Agents

11/03/2016

JCP Editors

Most oral antineoplastic drugs approved in the past six years are associated with multiple, clinically significant drug-drug interactions (DDIs). Therefore, the onus remains on oncologists to be more of aware DDIs...

Most...

11/03/2016

Journal of Clinical Pathways

Research in Review

Prior Malignancies Do Not Affect CML Outcomes

11/02/2016

JCP Editors

Patients with chronic myeloid leukemia (CML) and a history of prior malignancies appear to have the same outcomes as patients with no prior malignancies, according to a study published in Cancer. ------ Related...

...

11/02/2016

Journal of Clinical Pathways

Research in Review

Surveillance Superior to Standard Care for Melanoma

11/01/2016

JCP Editors

Specialized surveillance may be more cost effective and lead to fewer invasive procedures compared with standard care for patients with a high risk of melanoma, according to a study published in the Journal of...

...

11/01/2016

Journal of Clinical Pathways

Research in Review

Surgery Plus Chemoradiotherapy Better for Patients With Rectal Cancer

10/25/2016

JCP Editors

Patients with stage II or stage III rectal cancer may have better outcomes when treated with surgery and chemoradiotherapy than those who receive chemoradiotherapy alone, according to an article published in JAMA...

...

10/25/2016

Journal of Clinical Pathways

Research in Review

Treatment With Chemotherapy Drives Urothelial Cancer Resistance

10/21/2016

JCP Editors

Most patients with metastatic urothelial cancer will become resistant to therapy. New research published in Nature Genetics showed that chemotherapy also shapes the genetic evolution of remaining urothelial cancer...

Most...

10/21/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz: Week of October 16-22

10/20/2016

JCP Editors

A recent review of more than 10 years of published clinical data revealed that the use of what type of therapy in regimens for gastroenteropancreatic neuroendocrine tumors (GEPNETs) could improve outcomes, minimize...

A...

10/20/2016

Journal of Clinical Pathways

Research in Review

N-Acetyle Cysteine Improves Immunotherapy for Melanoma

10/18/2016

JCP Editors

Culturing T cells in N-acetyle cysteine (NAC) before they are infused as immunotherapy may improve effectiveness and outcomes in patients with melanoma, according to findings reported in Cancer Research....

...

10/18/2016

Journal of Clinical Pathways

Pharma Insights

Formulary Exclusion Lists Create Challenges for Pharma and Payers Alike

10/12/2016

Andrew Cournoyer, RPh, MBA

Larry Blandford, PharmD—Column Editor

The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...

The...

10/12/2016

Journal of Clinical Pathways